Fluarix Side Effects

Please note - some side effects for Fluarix may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

Fluarix Side Effects - for the Professional

Fluarix

Fluarix has been administered to 1,271 adults in clinical trials. Study Fluarix-US-001 was a randomized, double-blinded, placebo-controlled study that evaluated a total of 952 subjects: Fluarix n = 760, placebo n = 192. The population was 18 to 64 years of age (mean 39.1), 54% were female and 80% were Caucasian. Solicited adverse events were collected for 4 days (day of vaccination and the next 3 days). Unsolicited events that occurred within 21 days of vaccination (day 0-20) were recorded using diary cards supplemented by spontaneous reports and a medical history as reported by subjects.

Most events reported were considered by the subjects as mild and self-limiting. Table 2 provides the incidence of solicited adverse events for the Fluarix and placebo groups from Study Fluarix-US-001.

The adverse event information from clinical trials provides a basis for identifying adverse events that appear to be related to vaccine use and for approximating rates. However, because clinical trials are conducted under widely varying conditions, adverse event rates observed in the clinical trials of a vaccine cannot be directly compared to rates in the clinical trials of another vaccine, and may not reflect the rates observed in practice.

Total Vaccinated Cohort for safety included all vaccinated subjects for whom safety data were available.

a 4 days included day of vaccination and the subsequent 3 days.

Solicited and unsolicited adverse events following administration of Fluarix were collected in 3 additional studies. One randomized study enrolled adults >60 years of age. Two studies enrolled adults ≥18 years of age. From these 3 studies, a post-hoc analysis of solicited adverse events observed in the subsets of subjects ≥65 years of age (n = 245), pain was observed in 12.2%, redness in 15.9%, swelling in 16.7%, muscle aches in 10.2%, fatigue in 12.2%, headache in 14.3%, arthralgias in 11.0%, shivering in 6.9%, and fever in 0.4% of subjects.

Unsolicited adverse events from Study Fluarix-US-001 that occurred in ≥1% of recipients of Fluarix and at a rate greater than placebo included upper respiratory tract infection (3.9% vs. 2.6%), nasopharyngitis (2.5% vs. 1.6%), nasal congestion (2.2% vs. 2.1%), diarrhea (1.6% vs. 0%), influenza-like illness (1.6% vs. 0.5%), vomiting (1.4% vs. 0%), and dysmenorrhea (1.3% vs. 1.0%). One death due to atherosclerotic cardiovascular disease occurred 17 days after administration of Fluarix.

Incidence of Adverse Events of 1% to 10% in Non-US Clinical Trials With Fluarix

The following additional adverse events have been observed in non-US clinical trials with Fluarix.

General Disorders and Administrative Site Conditions: Malaise.

Local Reactions at Injection Site: Ecchymosis, induration.

Skin and Subcutaneous Tissue Disorders: Sweating.

Two deaths were reported in non-US trials with Fluarix: One death due to acute pancreatitis occurred 10 months after administration of Fluarix and one death due to abdominal neoplasm occurred 9 months after administration of Fluarix.

As with any vaccine, there is the possibility that broad use of Fluarix could reveal adverse events not observed in clinical trials.

Postmarketing Reports

Worldwide voluntary reports of adverse events received for Fluarix since market introduction of this vaccine are listed below. This list includes serious events or events which have causal connection to components of this or other vaccines or drugs. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to vaccine exposure.

Blood and Lymphatic System Disorders: Autoimmune hemolytic anemia, lymphadenopathy, thrombocytopenia.

Cardiac Disorders: Tachycardia.

Ear and Labyrinth Disorders: Vertigo.

Eye Disorders: Conjunctivitis, eye irritation, eye pain, eye redness, eye swelling, eyelid swelling.

Gastrointestinal Disorders: Abdominal pain or discomfort, nausea, swelling of the mouth, throat, and/or tongue.

General Disorders and Administrative Site Conditions: Asthenia, chest pain, chills, feeling hot, injection site mass, injection site reaction, injection site warmth, pain.

Immune System Disorders: Anaphylactic reaction including shock, anaphylactoid reaction, hypersensitivity, serum sickness.

Infections and Infestations: Injection site abscess, injection site cellulitis, pharyngitis, rhinitis, tonsillitis.

Musculoskeletal and Connective Tissue Disorders: Pain in extremity.

Nervous System Disorders: Convulsion, dizziness, encephalomyelitis, facial palsy, facial paresis, Guillain-Barré syndrome, hypoesthesia, myelitis, neuritis, neuropathy, paresthesia.

Respiratory, Thoracic and Mediastinal Disorders: Asthma, bronchospasm, cough, dyspnea, pneumonia, respiratory distress, stridor.

Skin and Subcutaneous Tissue Disorders: Angioneurotic edema, erythema, erythema multiforme, facial swelling, pruritus, rash, Stevens-Johnson syndrome, urticaria.

Vascular disorders: Henoch-Schönlein purpura, vasculitis.

Other Adverse Events

Immediate, presumably allergic, reactions (e.g., hives, angioedema, allergic asthma, and systemic anaphylaxis) rarely occur after influenza vaccination. Two subjects experienced urticaria in clinical trials of Fluarix. These reactions probably result from hypersensitivity to certain vaccine components, such as residual egg protein. Although Fluarix contains only a limited quantity of egg protein, this protein can induce immediate hypersensitivity reactions among persons who have severe egg allergy.3

The 1976 swine influenza vaccine was associated with an increased frequency of Guillain-Barré syndrome (GBS).3,10 Evidence for a causal relation of GBS with subsequent vaccines prepared from other influenza viruses is unclear.3 If influenza vaccine does pose a risk, it is probably slightly more than 1 additional case/1 million persons vaccinated.3

Neurological disorders temporally associated with influenza vaccination such as encephalopathy, optic neuritis/neuropathy, partial facial paralysis, and brachial plexus neuropathy have been reported.11,12

Microscopic polyangitis (vasculitis) has been reported temporally associated with influenza vaccination.13

Reporting of Adverse Events

The US Department of Health and Human Services has established a Vaccine Adverse Event Reporting System (VAERS) to accept all reports of suspected adverse events after the administration of any vaccine, including but not limited to the reporting of events required by the National Childhood Vaccine Injury Act of 1986.14 The VAERS toll-free number is 1-800-822-7967. Reporting forms may also be obtained at the VAERS website at www.vaers.hhs.gov.

Side Effects by Body System

Local

Local side effects have frequently included pain (54.7%), redness (17.5%), and swelling (9.3%). Ecchymosis, induration, injection site mass or abscess, injection site reaction or cellulitis, and warmth at the site of injection have also been reported.

Other

Other side effects have frequently included fatigue (19.7%), headache (19.3%), shivering (3.3%), and fever equal to/greater than 100.4 degrees Fahrenheit (1.7%). Malaise, sweating, vertigo, asthenia, chest pain, chills, and feeling hot have also been reported.

Musculoskeletal

Musculoskeletal side effects have frequently included muscle aches (23%) and arthralgia (6.4%). Pain in extremity has also been reported.

Hematologic

Hematologic side effects have included autoimmune hemolytic anemia, lymphadenopathy, and thrombocytopenia.

Cardiovascular

Cardiovascular side effects have included tachycardia, Henoch-Schonlein purpura, and vasculitis.

Ocular

Ocular side effects have included conjunctivitis, eye irritation, eye pain, eye redness, eye swelling, eyelid swelling.

Gastrointestinal

Gastrointestinal side effects have included abdominal pain or discomfort, nausea, swelling of the mouth, throat, and/or tongue.

Hypersensitivity

Hypersensitivity side effects have included anaphylactic reaction including shock, anaphylactoid reaction, hypersensitivity, and serum sickness.

Nervous system

Nervous system side effects have rarely included convulsion, dizziness, encephalomyelitis, facial palsy, facial paresis, Guillain-Barre syndrome, hypoesthesia, myelitis, neuritis, neuropathy, and paresthesia.

Respiratory

Respiratory side effects have included asthma, bronchospasm, cough, dyspnea, pneumonia, respiratory distress, stridor, pharyngitis, rhinitis, and tonsillitis.

Dermatologic

Dermatologic side effects have included angioneurotic edema, erythema, erythema multiforme, facial swelling, pruritus, rash, Stevens-Johnson syndrome, and urticaria.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.